Clinical effect of polaprezinc on cicatricial stenosis and stomach discharge function accompanied by gastric ulcer healing after endoscopic submucosal dissection.

Clinical effect of polaprezinc on cicatricial stenosis and stomach discharge function accompanied by gastric ulcer healing after endoscopic submucosal dissection. - Clinical effect of polaprezinc on cicatricial stenosis and stomach discharge function accompanied by gastric ulcer healing after endoscopic submucosal dissection.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010398

Enrollment

280

Registered

2013-04-02

Start date

2013-04-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric neoplasm performed ESD

Interventions

Promac Tablets 75 Takepron Tablets 30

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria are patients who are administered endoscopic submucosal dissection (ESD) and are over 20 years old.

Exclusion criteria

Exclusion criteria: 1) history of anaphylaxis to PPI 2) history anaphylaxis to polaprezinc 3) patients with zinc excess or doubt to zinc excess 4) patients with copper deficiency or doubt to copper deficiency 5) patients with aspirin asthma 6) patients with cicatrix at antrum of stomach 7) disagreement to the trial

Design outcomes

Primary

Measure	Time frame
level of cicatrical stenosis after endoscopic submucosal dissection	—

Secondary

Measure	Time frame
1 scar transition rate 2 decrease rate in ulcer size 3 level of granulation tuberalis 4 level of food debris	—

Countries

Japan

Contacts

Public ContactYoshimasa Miura

Jichi Medical University Hospital Department of Gastroenterology

y-miura@jichi.ac.jp0285-58-7348

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026